key: cord-0706286-7t73ezjb
authors: Sharma, Abhay
title: Low serum CCL17 as a marker for severe/critical COVID-19: a pathogenic link
date: 2021-02-11
journal: Gene
DOI: 10.1016/j.gene.2021.145486
sha: bb9eb7f9c380b73df9d402e7b72d0e5c9d143db7
doc_id: 706286
cord_uid: 7t73ezjb

nan

or from influenza A infection related pneumonia, with that in age-matched, uninfected control lungs showed downregulation of CCL17 and upregulation of IL6 and CXCL10 in COVID-19 alone, not influenza. What is more, the same study also found that between COVID-19 and influenza there is a differential abundance of T cell subset in the precapillary and postcapillary vessel walls in the lungs. With CCL17 as a ligand for T-lineage cell migration, and CCR4 as a dominant-type chemokine receptor for regulatory and helper T cells 3 , this finding is consistent with a role of CCL17 in COVID-19 lung pathology. Finally, on a different note, Sugiyama et al. mentions that theirs is a first report of low CCL17 expression in a disease state. Here, it may be noted that low tumor tissue levels of CCL17 has previously been identified as an adverse prognostic biomarker in clear cell renal cell carcinoma.

Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

CCR4 and its ligands: from bench to bedside

Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma

The author declares no competing interest.

COVID-19, Coronavirus Disease 2019